Proceed with caution on creating ‘biosimilar’ drugs
November 15, 2010
Dr. Edward Treadwell, Department of Internal Medicine at the Brody School of Medicine at East Carolina University in Greenville, N.C.
Buffalo News
Americans elected a new Congress on Nov. 2, but the voting booth wasn’t the only place where critical issues were at stake that day. Away from the spotlight of election news coverage, a committee of the federal Food and Drug Administration held a hearing in a Washington suburb on the future of biologic drugs, perhaps the most promising health care breakthrough of our lifetime.